WallStreetZenWallStreetZen

NASDAQ: NEO
Neogenomics Revenue

OverviewForecastEarningsRevenue
DividendOwnership
Neogenomics revenue was $660.57M for the trailing 12 months ending Dec 31, 2024, with N/A growth year over year. Quarterly revenue for the quarter (Q4 2024) ending on Dec 31, 2024 was $172.0M, up 2.5% from last quarter. For the last reported fiscal year 2024 ending Dec 31, 2024, NEO annual revenue was $660.6M, with 11.6% growth year-over-year.

NEO past revenue growth

How has NEO's revenue growth performed historically?

Company
11.65%
Industry
3.84%
Market
20.68%
NEO's revenue has grown faster... subscribe to Premium to read more.
Revenue Growth vs Industry Performance
NEO's revenue has grown slower... subscribe to Premium to read more.
Revenue Growth vs Market Performance
NEO's revenue growth is accelerating... subscribe to Premium to read more.
Accelerating Revenue Growth Performance

NEO revenue history

Current Revenue
$660.6M
Current Earnings
-$78.7M
Current Profit Margin
-11.9%

Be the first to know when NEO announces revenue.

NEO Revenue History By Year

NEO Yearly RevenueNEO RevenueNEO ChangeNEO Revenue Growth
2024-12-31$660.57M$68.92M+11.65%
2023-12-31$591.64M$81.92M+16.07%
2022-12-31$509.73M$25.40M+5.24%
2021-12-31$484.33M$39.88M+8.97%
2020-12-31$444.45M$35.62M+8.71%
2019-12-31$408.83M$132.09M+47.73%
2018-12-31$276.74M$36.49M+15.19%
2017-12-31$240.25M$8.44M+3.64%
2016-12-31$231.81M$132.01M+132.27%
2015-12-31$99.80M$12.73M+14.62%
2014-12-31$87.07M$20.60M+31.00%
2013-12-31$66.47M$6.60M+11.02%
2012-12-31$59.87M$16.38M+37.68%
2011-12-31$43.48M$9.11M+26.51%
2010-12-31$34.37M$4.90M+16.63%
2009-12-31$29.47M$9.45M+47.23%
2008-12-31$20.02M$8.51M+73.97%
2007-12-31$11.50M$5.03M+77.65%
2006-12-31$6.48M$4.59M+243.50%
2005-12-31$1.89M$1.33M+237.83%
2004-12-31$558.07k$188.10k+50.84%
2003-12-31$369.97k$276.48k+295.73%
2002-12-31$93.49k$92.49k+9,249.10%
2001-12-31$1.00kN/AN/A

1 of 2

Neogenomics Revenue FAQ

What was NEO's revenue last quarter?

On Invalid Date, Neogenomics (NASDAQ: NEO) reported Q4 2024 revenue of $172.00 million up 10.57% year over year. In the same quarter last year, Neogenomics's revenue was $155.55 million.

What was Neogenomics's revenue in 2024?

Neogenomics's annual revenue for the twelve months ending Dec 31, 2024 was $660.57 million, a 11.65% increase year over year.

How much does Neogenomics make in a day?

Based on Neogenomics annual revenue for the past five years, NEO makes an average of $1,474,363.84 per day.

What was Neogenomics's annual revenue growth in the past year?

As of Q2 2025, Neogenomics's revenue has grown 11.65% year over year. This is 7.81 percentage points higher than the US Diagnostics & Research industry revenue growth rate of 3.84%. Neogenomics's revenue in the past year totaled $660.57 million.

How much does Neogenomics make in a year?

Neogenomics's revenue by year for the past five years is:
  • Neogenomics's revenue for the twelve months ending Dec 31, 2024 was $660.57 million, a 11.65% increase year over year.
  • Neogenomics's annual revenue for Dec 31, 2023 was $591.64 million, a 16.07% increase from 2022.
  • Neogenomics's annual revenue for 2022 was $509.73 million, a 5.24% increase from 2021.
  • Neogenomics's annual revenue for 2021 was $484.33 million, a 8.97% increase from 2020.
  • Neogenomics's annual revenue for 2020 was $444.45 million, a 8.71% increase from 2019.
©2025 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.